MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.68
-0.04
-0.70%
Opening 10:04 01/15 EST
OPEN
5.68
PREV CLOSE
5.72
HIGH
5.76
LOW
5.67
VOLUME
41.13K
TURNOVER
--
52 WEEK HIGH
13.25
52 WEEK LOW
2.790
MARKET CAP
255.19M
P/E (TTM)
-19.5189
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11)
Benzinga · 3d ago
BRIEF-Medicinova Enters Into US$20 Mln Securities Purchase Agreement With A Fund Managed By 3D Investment Partners
reuters.com · 3d ago
MediciNova inks $20M securities purchase agreement with 3D Investment Partners
MediciNova (MNOV) has agreed to issue $20M in shares of its common stock to 3D Opportunity Master Fund, in a private placement transaction. Proceeds are expected to be used for
Seekingalpha · 3d ago
MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has entered into a Securities Purchase Agreement pursuant to which MediciNova has agreed to issue US$20 million in shares of its common stock to 3D Opportunity Master Fund, a fund managed by 3D Investment Partners Pte. Ltd. ("3D"), in a private placement transaction.
GlobeNewswire · 3d ago
MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis
The USPTO has issued a Notice of Allowance to MediciNova (MNOV) for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive
Seekingalpha · 12/29/2020 11:44
MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For Treatment Of Progressive MS
LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875),
Benzinga · 12/29/2020 11:31
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).
GlobeNewswire · 12/29/2020 11:30
The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14)
Benzinga · 12/15/2020 12:52
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNOV. Analyze the recent business situations of MediciNova Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNOV stock price target is 18.50 with a high estimate of 26.50 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 11.25M
% Owned: 25.05%
Shares Outstanding: 44.93M
TypeInstitutionsShares
Increased
12
201.47K
New
14
235.21K
Decreased
19
235.63K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.04%
Key Executives
Chairman/Independent Director
Jeffrey Himawan
President/Chief Executive Officer/Director
Yuichi Iwaki
Chief Financial Officer
Edward Stepanow
Vice President/IR Contact Officer
Geoffrey O'Brien
Vice President/IR Contact Officer
Geoffrey O'brien
Other/Director
Kazuko Matsuda
Director
Carolyn Beaver
Independent Director
Hideki Nagao
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MNOV
Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.